Plasma alpha-synuclein detected by single molecule array is increased in PD

Ann Clin Transl Neurol. 2019 Feb 15;6(3):615-619. doi: 10.1002/acn3.729. eCollection 2019 Mar.

Abstract

We utilized ultrasensitive single molecule technology to measure plasma alpha-synuclein in 221 subjects (51 controls, 170 PD). Plasma alpha-synuclein levels were significantly higher in PD than controls (15506.3 vs. 13057.0 pg/mL, P = 0.037), adjusting for age and gender. In PD, alpha-synuclein levels did not vary by H&Y stage or UPDRS motor scores but were significantly higher in PD patients with poorer cognition (MMSE ≤ 25) than controls (P = 0.016, Bonferroni corrected P = 0.047). Alpha-synuclein levels quantified using ultrasensitive single molecule technology discriminate PD from controls and correlate with cognitive severity. These preliminary findings require independent validation to determine the utility of this assay.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Female
  • Humans
  • Male
  • Middle Aged
  • Parkinson Disease / blood
  • Parkinson Disease / diagnosis*
  • Plasma
  • Single Molecule Imaging / methods*
  • alpha-Synuclein / blood*

Substances

  • alpha-Synuclein

Grants and funding

This work was funded by Singapore's National Medical Research Council grant ; Clinician‐Scientist New Investigator Grant grant CIRG/1416/2015; Singapore Translational Research grant NMRC/STaR/014/2013; Parkinson's disease Translational and Clinical Research grant TCR12dec010.